PeerVoice Oncology & Haematology Video

Marwan Fakih, MD - The Science and the Art of Sequencing Therapies in Advanced CRC Beyond the Second Line

Paul Wheatley-Price, MBChB, MD - The Track to Better Outcomes: Identifying and Managing Patients With NTRK-Positive Solid Tumours

Amy E. DeZern, MD, MHS - Small Words Make Large Differences: Best Practices in Supporting MDS Patients Across All Stages of Their Journey

Michael Chu, MD - A Smooth Ride: How to Optimize the Patient Journey With CAR T-Cell Therapy in Multiple Myeloma

Shawn Malone, MD, FRCPC - Maximizing Survival in mCRPC: Case-Based Guidance to Optimize Sequencing Decisions

Donna E. Reece, MD - Cases in Relapsed Refractory Multiple Myeloma: The Role of Anti-CD38–Based Regimens in an Evolving Canadian Landscape

Marwan Fakih, MD - Expert Lines of Thought in Sequencing Later Lines of Therapy in Advanced CRC

Ana C. Garrido-Castro, MD / Sarah L. Sammons, MD - TROP2-Directed Antibody-Drug Conjugates for Breast Cancer: The Clinical Significance of the Construct

Normand Blais, MD - Adjuvant Immunotherapy in Patients With Solid Tumours: Addressing Challenges With System Capacity in the Canadian Healthcare Setting

Eric Legius, MD, PhD - Building Blocks for Better Management of NF-1–Associated Plexiform Neurofibromas: Integrating New Evidence Into Canadian Clinical Practice

Elena Castro, MD, PhD - Radioligand Therapy and Therapeutic Sequencing in mCRPC

Brandon Sheffield, MD, FRCPC - Identifying Actionable Targets in Solid Tumours: The Importance of Comprehensive Genomic Profiling

Edward B. Garon, MD, MS - Abundance of Choice at First Line, Lack of Options Beyond: Addressing Unmet Needs in NSCLC Without Actionable Mutations

Christine Simmons, MD, MSc, FRCPC - Managing HR+/HER2- Metastatic Breast Cancer in the Community: Optimizing Safety to Maximize Benefit

Steven Mark Taylor, MD, FRCS(C), FACS - Beyond Face Value: The Case for Considering Immunotherapy in Locally Advanced cSCC

Rosalyn Juergens, MD, PhD - Why Precision Matters in NSCLC: Challenges and Solutions for Targeting Rare Oncogenic Driver Mutations in the Canadian Landscape

Angela Lamarca, MD, PhD, MSc - Overcoming Barriers to Better Care in CCA: Keys to Optimising Multidisciplinary Care, Molecular Testing, and Targeted Treatment

Karim Fizazi, MD, PhD - Radioligand Therapy for Prostate Cancer: Predicting Who May Benefit and Who May Not

Ken Herrmann, MD, MBA - Evolving Evidence of Radioligand Therapy in Metastatic Prostate Cancer: A 2023 Clinical Round-Up From Key Congresses

Brian I. Rini, MD, FASCO - Doubling and Tripling Up: Maximizing Outcomes With Combination Therapies in Renal Cell Carcinoma

Aditya Bardia, MD, MPH - When HER2 Is Low or Negative: Emerging Evidence on Antibody-Drug Conjugates for Hormone Receptor-Positive and Triple-Negative Breast Cancers

Aly-Khan A. Lalani, BSc(Hons), MD, FRCPC - Tailoring Immunotherapy-Based Combination Treatment in Advanced RCC: Key Updates to Refine Care

Karim Fizazi, MD, PhD - The Science and the Art of Modern Prostate Cancer Care: Improving Patient Outcomes Through Intensification and Individualisation of Treatment

Richard LeBlanc, MD - BCMA-Targeted Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma: Why, Who, and When

Lorenza Rimassa, MD - When One Size Doesn’t Fit All: Optimising Molecular Testing and Personalising Treatment Planning in Cholangiocarcinoma